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A b s t r a c t  
Release and permeation studies were carried out with the objective of developing 
transdermaltherapeutic systems with Ondansetron Hydrochloride (OS).The patches were 
prepared with Eudragit RSPO/RLPO as polymer and dibutylsebacate (DBS) and triethyl 
citrate (TEC) as the plasticizer in different compositions. Thickness, tensile strength, drug 
content, moisture content and water absorption studies of the patches were measured. In 
vitro release/permeation of OS was studied by using a Franz diffusion cell. Chemical 
enhancers like eugenol and Virgin linseed oil were added to compare the release pattern 
of the drug. All the formulations are developed and passed the mechanical as well as 
physiochemical properties, while in the case of release profile, the patch containing DBS 
had better percentage cumulative release compared to those with TEC containing 
patches. Eugenol acted as a good chemical enhancer as it increased percentage of 
permeation compared to linseed oil significantly. The ratio of Eudragit RSPO/RLPO (1:1) 
with combination of using 25% DBS as plasticizer and 3% eugenol as chemical enhancer 
favourable release profile.  The selected formulations may be used for further 
pharmacokinetic and pharmacodynamic studies in suitable animal models. 




Chemotherapy-induced nausea and vomiting (CINV) is a common 
side effect encountered by cancer patients during chemotherapy 
treatment. Ondansetron is a serotonin subtype 3 (5-HT3) receptor 
antagonist used in CINV management. Ondansetron 
hydrochloride (OS) is commercially available in oral and injectable 
forms. Orally administered OS undergoes extensive hepatic first-
pass metabolism, which accounts for its low bioavailability and 
short half-life [1-3]. It tends to be vomited before being absorbed 
and has limited use in patients with difficulty swallowing after 
chemotherapy [4]. As for intravenous administration, pain at 
injection site is the main limitation and onset of action is too rapid 
thus causing undesirable side effects such as headache, 
dizziness, and constipation [5]. Therefore, a new drug delivery 
system should be developed to improve OS therapeutic efficacy 
and patientÊs compliance.  
Transdermal drug delivery system (TDDS) is a topically 
administered medicament which delivers controlled amount of 
drug through the skin over certain period of time [6]. Polymers act 
as the backbone of systems for transdermal delivery and promote 
drug release in a pre-designed manner. Plasticiser is added to 
improve flexibility besides reducing patch brittleness [7-9]. 
Transdermal delivery of OS should be considered for use in CINV 
treatment since it promotes better patient compliance and 
unwanted side effects can be terminated by removing the patch 
from application site [10]. 
Gwaket al.,(2004) investigated the effects of vehicles on in vitro 
permeation of OS solution formulations across mouse skins and 
found that ethanol and water were the most effective vehicles [5]. 
However, they do not mix well with pressure-sensitive adhesive 
(PSA) so a further study was done using different vehicles to 
develop OS transdermal PSA matrix formulations [1]. Krishnaiahet 
al.,(2008) prepared hydroxypropyl cellulose gel drug reservoir 
formulations of OS and evaluated the effect of menthol (a 
penetration enhancer) on drug permeation across rat epidermis 
[10]. Pattnaiket al., (2011) [11] reported that chloroform was a 
preferred casting solvent for OS in transdermal films [5]. OS 
matrix type transdermal patches were prepared by using different 
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ratios of ethyl cellulose (EC) and polyvinylpyrrolidone (PVP) 
polymers [12] results showed that increased amount of PVP 
enhanced drug permeation. However, the flux achieved was 
significantly lower than the desired flux for effective transdermal 
delivery of OS and the need for permeation enhancement 
techniques was indicated [12].   
In the present study, OS transdermal matrix patches were 
developed by using Eudragit RSPO/RLPO as the polymer matrix 
with different percentages of dibutylsebacate (DBS) and triethyl 
citrate (TEC) as plasticisers. Eugenoland linseed oil were 
incorporated as chemical enhancer to increase drug permeability 
across the skin. Physicochemical properties, mechanical 
properties, in vitro drug release and permeation of OS matrix 
patches were studied. OS patch formulations were optimised 
based on experimental data, findings, and statistical analysis. 
Materials and Methods 
Materials 
Ondansetron hydrochloride (OS) was a gift from Aurobindo 
Chemicals, India. Eudragit RSPO and Eudragit RLPO were 
purchased from Evonik Rohm GmbH Pharma Polymers, 
Germany. Dibutylsebacate(DBS) and triethyl citrate (TEC) were 
purchased from Merck Chemicals. Virgin linseed oil B.P/EP grade 
was a gift sample from John L Seatons& Co Limited, UK. Eugenol 
was purchased Spectrum Chemical Mfg. Corp., USA.All other 
chemicals used in the study were of analytic reagent grade. 
Preparation of the patches 
For preparation of the patches, 500mg or 700mg of various ratios 
of Eudragit RSPO/RLPO were dissolved in a suitable solvent 
followed by slow magnetic stirring. Then the plasticizer (TEC or 
DBS, the amount of 15-25% the total polymer weight) and 16mg 
of drug (OS) were added to the solution and stirred for 15 to 20 
minutes. Finally the required amount of chemical enhancers such 
as linseed oil and eugenol (3% of the total weight of polymers) 
was added into selected patches and again stirred for 30 
minutes[13]. Next the total mass was slowly poured into the 
centre of stainless steel rings having a backing layer of aluminium 
foil. The total mass was dried at room temperature for 48 hours. 
The dried patches were kept in sealed plastic pouches and stored 
in desiccators until use (Table 1). 
Determination of patch thickness 
Thickness was measured using a digital micrometer.An average 
of three readings was obtained. The results are reported as an 
average of six readings (Table 2). 
Determination of tensile strength 
The tensile strength of the patches was evaluated using Instron 
4204 Tensile tester, with a 50KN load cell (Instron, UK). Six 
samples of each formulation were tested at an extension speed of 
5mm/min [American Society for Testing Materials (ASTM); 
method D 882- 75D]. The test was carried out at 25μ2ĈC and 56μ 






Where ĕ is the tensile strength; L 
max 
is the maximum load and A
i 
is the initial cross sectional area of the sample. The results are 
reported as an average of six readings (Table 2) [13]. 
Drug content 
A known area of each patch was weighed accurately and 
dissolved in 2mL chloroform followed by dilution with distilled 
water and then filtered. Drug content was analysed by UV 
spectrophotometer (PerkinElmer, USA) at 249nm. A drug-free film 
was used as a control [13]. An average of three readings was 
recorded. The results are reported as an average of six readings 
(Table 2). 
Moisture content 
Each patch was weighed and kept in a desiccator containing 
fused calcium chloride at 40ĈC for 24 hours. Patches were 
reweighed until a constant weight was obtained. An average of 
three readings was taken[13]. The results are reported as an 
average of six readings (Table 3). 
Water absorption studies 
Each patch was weighed and kept at room temperature for 24 
hours with exposure to two relative humidities of 75% (containing 
saturated sodium chloride solution) and 93% (containing 
saturated ammonium hydrogen phosphate solution) in different 
desiccators. Patches were reweighed until a constant weight was 
obtained [13]. An average of three readings was recorded. The 
results are reported as an average of six readings (Table 3). 
In vitro release studies 
In vitro release studies were carried out in a Franz diffusion cell 
(PermeGear, USA). A piece of circular matrix patch was mounted 
on receptor compartment, which was filled with freshly prepared 
phosphate buffered saline having pH 7.4. Temperature was 
maintained at 32 μ 0.5ĈC. Sample (0.5mL) was withdrawn every 
hour for 8 hours and being replaced immediately with same 
volume of saline solution [14]. Samples were then diluted and 
analysed by UV spectrophotometer at 249nm. An average of 
three readings was recorded (Table 4). 
In  vitro permeation studies 
A matrix patch was bound intimately with a section of freshly 
excised albino mouse abdominal skin on the receptor 
compartment. The skinÊs dermal side was kept in contact with the 
receptor liquid at all times to ensure continuous drug permeation. 
All other analysis conditions were similar to in vitro release studies 
[14]. An average of three readings was recorded (Table 4). 
Statistical analysis 
The results obtained were treated statistically using one-way 
analysis of variance (ANOVA). Post-hoc Tukey-HSD (Honestly 
Significant Difference) test was performed when there was a 
statistically significant difference, which was considered at p ª 
0.05. 
Results and Discussion 
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Thickness, tensile strength and drug content 
The formulation composition and results from these studies are 
presented in Tables 1& 2. Initially the patch was prepared by 
using total 500mg amount of blended RSPO/RLPO polymer and 
then examined its mechanical properties and showed the tensile 
strength about 5MPa with lesser thickness. However, we decided 
to enhance the tensile strength value above 5MPa, hence 
increased the blended amount up to 700mg of matrix patches 
(Table 1).  
Tensile testing of the patch allows analysis of mechanical 
properties, such as stress strain curves and stress at failure 
(strength). These properties are important since the patch must 
remain intact during storage or use.In this study one hydrophobic 
plasticizer, DBS and another hydrophilic plasticizer, TEC were 
added to determine if there were difference, in physiochemical 
and mechanical properties and in release profile prepared from 
this blended matrix patches. Table 1 shows that the patches 
containing TEC (0.09-0.18 mm) were thicker then patches using 
DBS as plasticizer (0.07-0.17 mm). Patches which were thinner 
were more favourable, for not affecting quality of life of patients 
and giving feel of bulkiness.5 For the tensile strength, patches 
containing TEC or DBS (4.93-8.25 MPA) passed the studies as 
their tensile strength all over 4 MPa, which is the value means the 
object is elastic in nature and not cracking or breaking easily [15]. 
Drug content of all formulation (425.78-427.81øgm/cm2) 
exceeded 99% of calculated drug content (423.59 øgm/cm2). For 
physiochemical properties studies, patches containing TEC 
showed significant higher readings compared with those 
containing DBS, due to hydrophilic nature of TEC [16]. 
The ultimate tensile strength value increases with increasing the 
blended ratio of RSPO grade. Table 1 shows clearly that there is 
no significant difference in mechanical properties between these 
two plasticizers. However, while increasing the percentage of from 
15% ă 25% of the both the plasticizers the tensile strength also 
increases considerably. Though DBS containing patches are 
slightly superior thanTEC containing patches in terms of tensile 
strength, thickness and physical appearance. This may be due to 
a higher miscibility of DBS plasticizer with the blended polymer 
matrix and OS. In Table 2 shows that the average drug content of 
all the patches is more than 99% of the intended amount and the 
most of the patches were elastic and flexible with an average 
tensile strength greater than 5MPa. Literature [17]and mechanical 
engineering handbooks show that materials that have an average 
tensile strength of more than 4.0 MPa are elastic in nature. 
Moisture content &water absorption studies 
The results of these studies are presented in Table 3. Water 
absorption and moisture content studies show that the storage 
and handling of such transdermal patches would be difficult if they 
did not have suitable properties. Table 3shows that the moisture 
content and water absorption capacities of the matrix patches are 
purely dependent on the concentration of plasticizer as well as 
amount of blended grades (either RSPO or RLPO) used in the 
study. The patches with lesser amount of hydrophobic RSPO 
grades containing combinations (15 to 25% :T1 ăT 16), have 
higher moisture contents and water absorption compared to the 
higher amount of RLPO grades (D1-D16).  
Similarly the water absorption at both RH conditions was also 
higher at higher amount of RLPO grades with TEC containing 
patches, because this excipient allows the water to more easily 
diffuse into the patch which leads to higher uptake of moisture 
and water absorption [18]. The relatively more hydrophobic DBS 
& RSPO grade containing patches are more difficult to hydrate 
during the moisture content and water absorption studies, 
especially at 15%. From Table 3 it is clear that the water uptake 
and capacity of both types of patches remain intact when fully 
hydrated. 
In vitro release studies 
The percentage cumulative release and release rate after 8 hrs 
from different plasticized OS matrix patches are shown in Table 4. 
The cumulative release of drug on a percentage basis from the 
matrix patch with and without enhancers was plotted against time 
(t1/2) in Fig. 1 and Fig. 2. Plots which are having Higuchi pattern & 
optimum release formulations are only presented.Figure 1 & 2 
plots represent cumulative percentage release of OS from the 
patches which contain DBS and TEC plasticizer respectively. 
From the figure 1, the release pattern from the DBS contained 
patches D 5 ă D 12, it is observed that they follow FickÊs law of 
diffusion, it is also clear that the release of the drug from the 
patches followed the diffusion controlled matrix model in which the 
total percentage of drug released is proportional to square root of 
time. 
In the case of TEC contained patches, the cumulative percent 
release of drug from the range of 4% - 30% after 8 hrs. It may be 
due to plasticizing effect of TEC is lesser to that of DBS. It may be 
due to three main reasons (i). hydrophilic TEC leaches from the 
patch, resulting in decreasing plasticizer content and thus 
decreasing diffusivity [15]. (ii). greater degree of coalescence of 
the methacrylate polymer particles into a patch for a given set of 
processing conditions with increasing plasticizer level [19]. (iii). 
during the release studies, the patch is in contact with the release 
medium, hence water-filled cavities/channels are created, and 
drug transport also occurs via diffusion through these domains. 
Release profile with enhancers 
Each formulation was added 3% linseed oil and 3% eugenol 
respectively. The percentage cumulative releases with chemical 
enhancer containing matrix patches are shown in Table 5. 
It can be seen that as the percentage release increases with 
eugenol significantly higher permeation (DE 9, DE 10 and DE 13: 
62% ă 84%) than for the corresponding without enhancer patch 
(D 9, D 10 and D13: 42% ă 54%). In the case of linseed oil 
containing patches having lesser cumulative percent release than 
eugenol it may be either linseed oil blocks the pores or acts as a 
secondary plasticizer to prevent drug diffusional pathor 
hydrophobic nature of the linseed oil does not allow the drug 
easily into the phosphate buffer saline solution. Statistical findings 
showed there was significant different to the effect of adding 
chemical enhancer (p=0.07-0.11). 
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Ex vivo Permeation Studies 
After review of all the factors including mechanical and 
physiochemical properties, percent release, release rate, patch 
quality before and after release by visual examination, surface 
smoothness and the effect of permeation enhancers, from DBS 
contained patches (D1, D3, D5, D9, DL10, DL13, DE9, DE10, 
DE13) were selectedfor skin permeation studies. Each selected 
formulation was evaluated using the mouse skin model, and the 
average of three determinations reported. The cumulative percent 
permeation after 8 hrs through RSPO/RLPO matrix patches and 
mouse skin are shown in Table 6. 
From this data, it can be seen that the DE 9, DL 10 and DL 13 
matrix patches have the highest permeation, 47%, 55% and 58% 
respectively. Henceboth linseed oil and eugenolare more suitable 
enhancerswith RSPO/RLPO; Eugenolprobably modify the solvent 
nature of the stratum corneum, improving drug partioninginto the 
tissue and it may also modify drug diffusivity through the 
membrane and bring about a reduction of the lag time for 
permeation, indicating an increase in the diffusivity of the drug 
through the skin membrane [20]. In the case of linseed oil the 
cumulative percent release of OS highest compare to all the 
formulations such as 55% and 58% (DL 10 and DL 13) 
respectively. Permeation of linseed oil into the lipid layers of the 
skin may lead to the change in the lipid barrier properties. Further 
disruption of the stratum corneum barrier by the abrading agent 
might enhance the permeation by removing the upper dead 
stratum corneum.This may be probably because the primary 
pathway of transdermally delivered drugs is paracellular, i.e. 
around the cells than through the elastin. Elastin is composed of 
collagen and hyaluronic acid and other lipids, which occupies the 
interstices between the cells of the top-most layer of the skin (i.e. 
the epidermis, including, e.g. stratum corneum, lucidum, 
granulosum, spinosus) and must be dissolved and/or disrupted in 
order for the drug to be able to transverse through the viable skin 
to the subcutaneous tissues where the cutaneous plexi of the 
capillary net can be reached [21].  
The cumulative percent permeation and permeation rate from 
patches without any enhancers (D 1, D 3, D 5and D 9) was lower 
compare to others.The in vitro drug release and skin permeation 
studies showed that the skin is the rate-limiting factor because the 
in vitro release of the drug was greater from each type of the 
matrix patch compared with the respective in vitro drug 
permeation rate. Thecumulative drug permeation as a percentage 
from all the patches was plotted against the permeation time in 
hours (t) in figure 3. In each plot, the rate of drug permeation is 
fairly constant over time and the permeation profiles exhibit the 
concentration dependent first-order kinetics. 
Conclusion 
The percentage release and permeation from the Eudragit 
RSPO/RLPO blended matrix patch formulations plasticized with 
DBS and containing either 3% eugenol or linseed oil  80 are 
higher than for thecorresponding TEC containing 
formulations.Patch thickness was lower and tensile strength was 
higher compared to TEC containing patches. From the above 
observations, it may be concluded that the blended ratios of the 
eudragit RSPO/RLPO (50:50 or 60:40), the plasticizer DBS(20- 
25%) and addition of 3% eugenol as well as  linseed oil as 
chemical enhancersto be needed for better  release percentages 
of ondansetron hydrochloride. The patch formulations DE9, DL 10 
and DL 13 were the best TD matrix patch compositions in 
thispresent study for the uniform and continuous 
release/permeation of OS over an extended period, and to 
maintain a sustained therapeutic level of the drug in plasma. 
These selected formulations may be used for further 
pharmacokinetic and pharmacodynamic studies in suitable animal 
models. 
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Table 1. Patch composition and formulations  
Sr. no. Patch Composition Total Polymer 
Weight (mg) 
Patch Code 
RSPO : RLPO % Plasticizer  % Plasticizer  
1 50 : 50 500 15% TEC T1 15% DBS D1 
2 60 : 40 500 T2 D2 
3 70 : 30 500 T3 D3 
4 80 : 20 500 T4 D4 
        
5 50 : 50 700 15% TEC T5 15% DBS D5 
6 60 : 40 700 T6 D6 
7 70 : 30 700 T7 D7 
8 80 : 20 700 T8 D8 
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9 50 : 50 700 20% TEC T9 20% DBS D9 
10 60 : 40 700 T10 D10 
11 70 : 30 700 T11 D11 
12 80 : 20 700 T12 D12 
        
13 50 : 50 700 25% TEC T13 25% DBS D13 
14 60 : 40 700 T14 D14 
15 70 : 30 700 T15 D15 
16 80 : 20 700 T16 D16 
*RSPO: Eudragit® RSPO RLPO: Eudragit® RLPO, polymer used for matrix-based transdermal formulations. TEC: Tri-ethyl citrate, DBS: Di-butyl sebacate, 
both are plasticizers added into patch formulations. 
 
 






















Patch Code Average Thickness (mm) Average Tensile strength (MPa) Average Drug content (µgm/cm2) 
TEC DBS TEC DBS TEC DBS TEC DBS 
T1 D1 0.10 0.08 4.93 ± 0.9 5.34 ± 0.2 426.45 426.98 
T2 H2 0.10 0.08 5.82 ± 0.8 6.07 ± 0.5 426.57 426.70 
T3 H3 0.09 0.07 5.93 ± 0.5 6.65 ± 0.3 426.15 427.01 
T4 H4 0.09 0.07 5.73 ± 0.4 6.83 ± 0.9 426.38 427.10 
T5 D5 0.15 0.124 5.83 ± 0.5 6.63 ± 0.6 426.71 426.89 
T6 D6 0.15 0.13 6.12 ± 0.7 7.24 ± 0.7 426.52 427.57 
T7 D7 0.14 0.13 6.67 ± 0.6 7.46 ± 0.4 426.87 427.09 
T8 D8 0.13 0.12 7.18 ± 0.4 7.97 ± 0.2 426.79 427.64 
T9 D9 0.18 0.16 6.15 ± 0.5 6.94 ± 0.4 426.03 427.06 
T10 D10 0.17 0.16 6.53 ± 0.7 7.78 ± 0.6 426.08 427.10 
T11 D11 0.17 0.16 7.18 ± 0.4 7.94 ± 0.1 426.19 427.64 
T12 D12 0.16 0.15 7. 74± 0.6 8.25 ± 0.4 426.51 427.81 
T13 D13 0.18 0.17 5.95 ± 0.5 6.97 ± 0.3 425.78 426.97 
T14 D14 0.17 0.17 6.41 ± 0.2 7.25 ± 0.5 425.83 427.08 
T15 D15 0.18 0.16 6.72 ± 0.4 7.37 ± 0.6 426.08 427.19 
T16 D16 0.18 0.16 6.97 ± 0.9 7.58 ± 0.7 426.47 427.67 
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Table 3.Moisture content and water absorption studies. 
Patch Code % Plasticizer Moisture content (wt %) Water absorption (wt %) 
TEC DBS 
T1 D1 15 15 1.43 1.06 2.92 5.08 1.89 2.67 
T2 D2 15 15 1.31 1.01 2.73 4.82 1.61 2.48 
T3 D3 15 15 1.20 0.92 2.59 4.67 1.48 2.31 
T4 D4 15 15 1.09 0.89 2.41 4.57 1.09 2.07 
T5 D5 15 15 1.91 1.20 3.09 4.91 2.08 3.08 
T6 D6 15 15 1.84 1.10 2.83 4.8 1.73 2.79 
T7 D7 15 15 1.67 1.01 2.67 4.59 1.51 2.51 
T8 D8 15 15 1.46 0.94 2.58 4.43 1.38 2.28 
T9 D9 20 20 2.09 1.15 2.09 4.09 1.7 3.02 
T10 D10 20 20 1.90 1.08 1.87 3.91 1.51 2.72 
T11 D11 20 20 1.82 0.96 1.64 3.52 1.37 2.58 
T12 D12 20 20 1.64 0.91 1.52 3.19 1.27 2.40 
T13 D13 25 25 2.13 1.07 2.20 4.16 1.51 2.92 
T14 D14 25 25 2.03 0.97 2.07 3.95 1.38 2.57 
T15 D15 25 25 1.93 0.86 1.82 3.82 1.21 2.34 
T16 D16 25 25 1.68 0.74 1.67 3.57 1.16 2.08 
 
Table 4.Cumulative percentage release and release rate after 8 hours with permeation enhancer. 
Patch Code Percentage of diffusion (%) Diffusion rate (μgm/cm2/hr) 
T1 D1 4.752 53.912 0.174 9.983 
T2 D2 24.357 43.239 32.11 5.752 
T3 D3 14.176 53.364 0.079 29.98 
T4 D4 9.033 44.797 3.194 2.411 
T5 D5 9.169 50.346 8.354 9.443 
T6 D6 9.446 45.141 16.87 17.48 
T7 D7 3.740 40.092 0.370 1.392 
T8 D8 3.529 29.637 0.033 4.256 
T9 D9 21.627 54.581 4.355 2.024 
T10 D10 26.206 45.116 8.473 0.171 
T11 D11 21.957 28.451 0.053 1.320 
T12 D12 24.870 23.158 31.91 0.172 
T13 D13 24.284 42.851 3.623 0.996 
T14 D14 28.763 23.555 5.985 1.010 
T15 D15 30.379 29.242 7.932 0.970 
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Table 5.Cumulative percentage release after 8 hours with permeation enhancer 
Patch Code 
Patch code for formulations with chemical enhancers 






D 9 DL 9 37.75 DE 9 62.08 
D 10 DL 10 51.43 DE 10 78.67 
D 13 DL 13 57.34 DE 13 84.82 
 
Table 6.Cumulative percentage permeation and rate after 8 hours. 
Patch 
Code 




D1 23.537 8.64 
D3 23.286 12.57 
D5 24.102 16.14 
D9 26.847 21.04 
DL10 27.686 22.14 
DL13 42.648 25.47 
DE9 47.746 20.49 
DE10 55.437 22.14 
DE13 58.380 26.37 
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Figure 1 Release profile of OS 
 
 
Figure 2 Release profile of OS 
 
